Italy's GVS FY revenue rises on healthcare & life sciences strength

GVS

26/03/2026 12:20

Overview

Italy filtration solutions firm's FY 2025 revenue up 2% at constant FX, slight miss vs estimates

Adjusted EBITDA up 3%, slightly beating analyst expectations

Adjusted EBIT exceeded analyst estimates

Outlook

GVS expects low single-digit revenue growth at constant FX in FY2026 vs. FY2025

Company sees adjusted EBITDA margin expansion of 20–50 bps in FY2026 vs. FY2025

GVS expects leverage ratio of about 1.8x as of December 31, 2026

Result Drivers

HEALTHCARE & LIFE SCIENCES - Division revenue up 1.5% at constant FX, supported by Haemonetics' Whole Blood acquisition; US hemodialysis sales declined

SAFETY DIVISION GROWTH - Safety division revenue up 11.9% at constant FX

ENERGY & MOBILITY DECLINE - Energy & Mobility division revenue down 7.5% at constant FX, weighing on overall growth

Company press release: ID:nBIA8zsGgG

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Slight Miss*
EUR 424.70 mln
EUR 427.88 mln (5 Analysts)
FY Adjusted EBITDA
Slight Beat*
EUR 107 mln
EUR 105.94 mln (5 Analysts)
FY Adjusted EBIT
Beat
EUR 75.80 mln
EUR 72.50 mln (5 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for GVS SpA is €5.30, about 41.3% above its March 25 closing price of €3.75

The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 14 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)